Navigation Links
Stem cells used to model infant birth defect
Date:3/18/2010

Boston, Mass. -- Hemangiomas -- strawberry-like birthmarks that commonly develop in early infancy are generally harmless, but up to 10 percent cause tissue distortion or destruction and sometimes obstruction of vision or breathing. Since the 1960s, problematic hemangiomas have been treated with corticosteroids such as dexamethasone or prednisone. But steroids have considerable side effects, don't always work, and their mechanism of action in hemangioma has remained a mystery. Researchers at Children's Hospital Boston recently discovered that infantile hemangiomas originate from stem cells, and have used these stem cells to better understand this tumor in the laboratory. In the March 18 issue of the New England Journal of Medicine, they show that steroids target hemangioma stem cells specifically, reveal their mechanism of their action and suggest other possible ways to halt and shrink hemangiomas.

Hemangiomas, affecting 4 to 10 percent of infants, are noncancerous tumors consisting of a tangled mass of blood vessels. Previously, it was assumed that steroids act on endothelial cells, which make up about 30 percent of cells in the tumor. The new research, led by dermatologist Shoshana Greenberger, MD, PhD, working in the lab of Joyce Bischoff, PhD, in Children's Vascular Biology Program, shows that steroids interfere with a much rarer and more primitive cell type hemangioma stem cells.

Greenberger and Bischoff further showed that steroids work by inhibiting hemangioma stem cells' ability to stimulate blood vessel growth, and that they do so by shutting down production of a specific factor called vascular endothelial growth factor (VEGF-A). VEGF is well known as a stimulator of angiogenesis (blood vessel growth) in cancer and age-related macular degeneration.

"We now have more therapies targeting VEGF, so our findings open the way to finding a more specific and safer therapy for hemangioma," says Greenberger.

Steroids usually result only in stabilization of hemangioma growth, and about 30 percent of hemangiomas don't respond to steroid treatment. Steroids also have side effects including facial swelling, hyperactivity, growth retardation and increased blood pressure. Although the effects on appearance may seem minor, research indicates that a baby's physical appearance can interfere with maternal bonding.

"My dream has always been to give a drug to stop hemangioma at its first appearance," says Children's plastic surgeon John Mulliken, MD, co-director of Children's Vascular Anomalies Center and a co-author on the study.

Greenberger, Bischoff and colleagues worked with hemangioma stem cells isolated from patient tissue samples provided by Mulliken, and showed that:

  • When human hemangioma stem cells were pretreated with dexamethasone, then implanted in mice, the tumors that formed had far fewer blood vessels.
  • Dexamethasone suppressed the stem cells' production of VEGF-A, but did not suppress VEGF-A production by endothelial cells from the same hemangioma.
  • When VEGF-A production was suppressed in hemangioma stem cells using shRNA silencing, then implanted in the mice, there was an 89 percent reduction in vessel growth.
  • VEGF-A was detected in actively growing hemangiomas, but not in regressing (involuting) hemangiomas.

Earlier research in Bischoff's lab and that of Bjorn Olsen, MD, PhD, of the Harvard School of Dental Medicine, indicates that hemangiomas may result from an in utero mutation in a stem cell destined to become an endothelial cell, causing a disruption in the normally well-ordered process of blood vessel development. Under a 2008 Translational Research Program grant from Children's, Bischoff's lab has been using hemangioma stem cells to test a library of existing medications that might specifically inhibit the proliferation of the hemangioma stem cells, and thereby limit growth of the hemangioma tumor.

"Steroids are inhibiting expression of a central regulator of blood vessel growth: VEGF-A," says Bischoff. "But we'd like to target the stem cell itself stop its proliferation, prevent it from differentiating into unwanted blood vessels and, at the same time, eliminate the cellular source of VEGF-A."


'/>"/>

Contact: Keri Stedman
keri.stedman@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related biology news :

1. ESF EURYI award winner aims to stop cancer cells reading their own DNA
2. Newly created cancer stem cells could aid breast cancer research
3. AIDS interferes with stem cells in the brain
4. Clemson scientists shed light on molecules in living cells
5. Social habits of cells may hold key to fighting diseases
6. UF scientists reveal how dietary restriction cleans cells
7. Human derived stem cells can repair rat hearts damaged by heart attack
8. Scientists identify embryonic stem cells by appearance alone
9. Cells united against cancer
10. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
11. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron ... LLP as an associate in the firm’s Intellectual Property practice group. , Clients ... electromechanical patent applications. He has an electrical engineering and computer engineering background, and ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... The ... has been selected as one of three finalists for the European Inventor Award 2016 ... annual innovation prize will be announced at a ceremony in Lisbon on June 9th. ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business for ... multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The SI ... team,” said John Younger, founder of Accolo. “We are growing and his experience ...
Breaking Biology Technology: